论文部分内容阅读
目的:探讨FEN-1和AXL在上皮性卵巢癌组织表达情况及其与卵巢癌化疗耐药的关系。方法:采用免疫组化法检测卵巢癌/正常卵巢组织中FEN-1及AXL表达,分析蛋白表达与卵巢癌化疗疗效相关性。结果:卵巢癌组织中FEN-1及AXL阳性率分别为58.20%及72.13%,均显著高于正常卵巢组织(10%)(P<0.05)。相对早期患者,FEN-1高表达于晚期卵巢癌组织(37.50%&63.27%)(P<0.05),与分化程度及化疗敏感性关系不大(P>0.05)。AXL高表达于晚期卵巢癌(77.55%&50%)及低分化组织中(79.71%&62.26%)(P<0.05)。癌组织AXL阳性者化疗有效率(51.14%)明显低于阴性者(85.29%)(P<0.05);化疗耐药组AXL阳性率(89.58%)明显高于敏感组(60.81%)(P<0.05)。结论:FEN-1及AXL均与卵巢癌发生发展相关,AXL的表达可作为预测卵巢癌化疗耐药的指标。
Objective: To investigate the expression of FEN-1 and AXL in epithelial ovarian cancer and its relationship with chemoresistance in ovarian cancer. Methods: The expression of FEN-1 and AXL in ovarian cancer / normal ovary tissue was detected by immunohistochemistry. The correlation between the protein expression and the curative effect of ovarian cancer was analyzed. Results: The positive rates of FEN-1 and AXL in ovarian cancer tissues were 58.20% and 72.13%, respectively, which were significantly higher than those in normal ovarian tissues (10%) (P <0.05). FEN-1 was highly expressed in advanced ovarian cancer (37.50% & 63.27%) (P <0.05), but not in differentiation and chemosensitivity (P> 0.05). AXL was highly expressed in advanced ovarian cancer (77.55% & 50%) and in poorly differentiated tissues (79.71% & 62.26%) (P <0.05). The positive rate of chemotherapy for AXL positive patients (51.14%) was significantly lower than that of negative patients (85.29%) (P <0.05). The positive rate of AXL in chemotherapy resistant group (89.58%) was significantly higher than that in sensitive group (60.81%) (P < 0.05). Conclusions: Both FEN-1 and AXL are associated with the development of ovarian cancer, and the expression of AXL may be used as an index to predict the chemoresistance of ovarian cancer.